Download full report with analyst certification and important disclosures
Jul 28 2020, 07:10 IST/BST
Uniphar
Track record building nicely; re-rating has much further to go
- Sectors : Pharma and healthcare
- Companies : Uniphar
DAVY VIEW
Uniphar has traded well through H1 2020, highlighting both the growth and resilience inherent in its diversified healthcare services model. Central to our investment thesis is the view that Uniphar’s multiple should materially re-rate as it builds its track record post IPO. We raise our 12-month price target to €2.35 (>20% upside) but argue that a €3.00-3.35 share price is a credible possibility in a couple of years if the company continues to execute.
